Smart-ring maker Oura is facing a proposed class action that challenges how it markets the accuracy of its sleep tracking. The complaint, filed by Clarkson Law Firm in San Francisco, alleges that the devices cannot directly measure the physiological signals required to determine sleep stages and instead provide AI-generated estimates that consumers may mistake for clinical measurements.
These are allegations, not findings by a court. Oura had not responded to TechCrunch’s request for comment when the source article was published, leaving the company’s technical and legal defence absent from the report. The dispute therefore concerns claims made in a complaint rather than independently established product failure.
The lawsuit targets accuracy claims
Oura rings are priced from $300 and are promoted as tools for monitoring sleep and its different stages. According to the complaint, the company has described its products as highly accurate and has cited figures ranging from 79% measurement accuracy to 95% sleep-staging accuracy compared with clinical sleep laboratories.
The plaintiffs argue that a ring worn on a finger cannot observe the brain activity, eye movement and other signals used in clinical sleep studies. On that basis, they allege that the device estimates sleep stages through algorithms rather than measuring them directly. The complaint characterises those estimates as no better than chance, but TechCrunch does not present an independent technical assessment supporting that characterisation.
The case also points to user complaints posted online. Some people have reported a mismatch between feeling that they slept poorly and receiving an optimal sleep assessment from the ring. Others have questioned its ability to identify sleep cycles. Such accounts demonstrate dissatisfaction but do not by themselves establish the overall error rate across all users.
The proposed class action seeks an order requiring Oura to stop what the plaintiffs describe as deceptive advertising. It also asks for restitution for consumers who allegedly purchased rings based on misleading accuracy claims. Whether those requests proceed will depend on the court accepting the case and evaluating evidence from both sides.
AI estimates are not the same as direct measurement
The central distinction is between sensing and inference. A wearable can collect signals available at the wrist or finger, then use software to estimate a state that it cannot observe directly. That approach is common in consumer health technology, but its usefulness depends on validation, uncertainty and how clearly the result is explained.
An estimate can still provide useful information without matching a hospital test. The source article does not compare Oura’s performance with alternative wearables or analyse the studies behind the company’s published accuracy figures. It therefore cannot establish whether the ring is clinically inadequate, generally useful or suitable only for tracking broad trends.
The lawsuit instead asks whether Oura’s marketing communicates those limitations accurately. A percentage can appear precise while concealing how performance varies by person, sleep stage or testing method. Consumers may also treat a daily score as a diagnosis even when the device is intended as a wellness tool.
That distinction matters because sleep information can influence how people interpret fatigue, plan activity and judge their health. The plaintiffs say inaccurate results may change behaviour. TechCrunch reports that claim but does not document a specific medical injury attributed to the ring.
A legal challenge could test wearable transparency
The complaint arrives after years of online discussion about consumer sleep tracking, but a lawsuit requires more than public frustration. Plaintiffs will need to substantiate what Oura can and cannot measure, how its models generate sleep stages and whether reasonable buyers were misled by the company’s language.
Oura may respond with validation studies, product disclaimers or a different interpretation of its marketing. None was available in TechCrunch’s initial report, making it too early to assess the strength of the defence or predict the outcome.
The broader issue is how makers of AI-assisted health devices describe probabilistic outputs. Clear labels about what is sensed, what is inferred and how uncertainty is calculated can help users understand the difference between consumer guidance and clinical evidence. The court case may clarify whether Oura met that standard, but it has not yet done so.
